http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 10 Jun 2026 07:13:13 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Actuate+Therapeutics+%28ACTU%29/26626511.html <p>H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $15.00 price target on Actuate Therapeutics (NASDAQ: ACTU).</p><p>The analyst commented: "On June 9, Actuate announced elraglusib's inclusion in a multi-arm, multi-stage, randomized, open-label Phase 1/2 study, BEACON2, to evaluate the drug as a therapy for pediatric relapsed or refractory neuroblastoma (NBL). Elraglusib is expected to be combined with dinutuximab beta and chemotherapy. The study, sponsored and operated by the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham, is designed to determine safety, MTD, RP2D, and PK in a cohort of up to 20 patients initially. If http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Actuate+Therapeutics+%28ACTU%29/26626511.html Wed, 10 Jun 2026 07:13:13 -0400 ACTU http://www.streetinsider.com/Corporate+News/Actuate%27s+elraglusib+selected+for+BEACON2+pediatric+neuroblastoma+trial/26620365.html <p>Actuate Therapeutics Inc. (NASDAQ: ACTU) announced that its drug candidate elraglusib will be evaluated in the BEACON2 clinical trial for children with relapsed and refractory neuroblastoma.</p><p>The BEACON2 trial is a multi-arm, multi-stage Phase 1/2 platform study conducted by the Cancer Research UK Clinical Trials Unit at the University of Birmingham. Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in up to 20 patients initially to determine safety, maximum tolerated dose, and recommended Phase 2 dose.</p><p>The combination may advance to a randomized portion of the trial with approximately 75 patients if the initial phase shows positive results. The http://www.streetinsider.com/Corporate+News/Actuate%27s+elraglusib+selected+for+BEACON2+pediatric+neuroblastoma+trial/26620365.html Tue, 09 Jun 2026 07:45:44 -0400 ACTU http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html <p align="center"><em>- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham </em><br/><br/><em>- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma</em><br/><br/><em>- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers</em></p> <p align="center"><em>- Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma</em></p> <p>CHICAGO and FORT WORTH, Texas, June 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html Tue, 09 Jun 2026 07:45:00 -0400 A.14055798 A.23386119 ACTU O.00573638 O.00847036 O.46993908 http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html <p align="center"><em>- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham </em><br/><br/><em>- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma</em><br/><br/><em>- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers</em></p> <p align="center"><em>- Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma</em></p> <p>CHICAGO and FORT WORTH, Texas, June 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html Tue, 09 Jun 2026 07:45:00 -0400 A.14055798 A.23386119 ACTU O.00573638 O.00847036 O.46993908 http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html <p align="center"><em>- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham </em><br/><br/><em>- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma</em><br/><br/><em>- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers</em></p> <p align="center"><em>- Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma</em></p> <p>CHICAGO and FORT WORTH, Texas, June 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html Tue, 09 Jun 2026 07:45:00 -0400 A.14055798 A.23386119 ACTU O.00573638 O.00847036 O.46993908 http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html <p align="center"><em>- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham </em><br/><br/><em>- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma</em><br/><br/><em>- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers</em></p> <p align="center"><em>- Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma</em></p> <p>CHICAGO and FORT WORTH, Texas, June 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html Tue, 09 Jun 2026 07:45:00 -0400 A.14055798 A.23386119 ACTU O.00573638 O.00847036 O.46993908 http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html <p align="center"><em>- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham </em><br/><br/><em>- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma</em><br/><br/><em>- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers</em></p> <p align="center"><em>- Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma</em></p> <p>CHICAGO and FORT WORTH, Texas, June 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html Tue, 09 Jun 2026 07:45:00 -0400 A.14055798 A.23386119 ACTU O.00573638 O.00847036 O.46993908 http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html <p align="center"><em>- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham </em><br/><br/><em>- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma</em><br/><br/><em>- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers</em></p> <p align="center"><em>- Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma</em></p> <p>CHICAGO and FORT WORTH, Texas, June 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html Tue, 09 Jun 2026 07:45:00 -0400 A.14055798 A.23386119 ACTU O.00573638 O.00847036 O.46993908 http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html <p align="center"><em>- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham </em><br/><br/><em>- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma</em><br/><br/><em>- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers</em></p> <p align="center"><em>- Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma</em></p> <p>CHICAGO and FORT WORTH, Texas, June 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html Tue, 09 Jun 2026 07:45:00 -0400 A.14055798 A.23386119 ACTU O.00573638 O.00847036 O.46993908 http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html <p align="center"><em>- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham </em><br/><br/><em>- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma</em><br/><br/><em>- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers</em></p> <p align="center"><em>- Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma</em></p> <p>CHICAGO and FORT WORTH, Texas, June 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html Tue, 09 Jun 2026 07:45:00 -0400 A.14055798 A.23386119 ACTU O.00573638 O.00847036 O.46993908 http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html <p align="center"><em>- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham </em><br/><br/><em>- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma</em><br/><br/><em>- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers</em></p> <p align="center"><em>- Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma</em></p> <p>CHICAGO and FORT WORTH, Texas, June 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html Tue, 09 Jun 2026 07:45:00 -0400 A.14055798 A.23386119 ACTU O.00573638 O.00847036 O.46993908 http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html <p align="center"><em>- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham </em><br/><br/><em>- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma</em><br/><br/><em>- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers</em></p> <p align="center"><em>- Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma</em></p> <p>CHICAGO and FORT WORTH, Texas, June 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html Tue, 09 Jun 2026 07:45:00 -0400 A.14055798 A.23386119 ACTU O.00573638 O.00847036 O.46993908 http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html <p align="center"><em>- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham </em><br/><br/><em>- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma</em><br/><br/><em>- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers</em></p> <p align="center"><em>- Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma</em></p> <p>CHICAGO and FORT WORTH, Texas, June 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html Tue, 09 Jun 2026 07:45:00 -0400 A.14055798 A.23386119 ACTU O.00573638 O.00847036 O.46993908 http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html <p align="center"><em>- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham </em><br/><br/><em>- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma</em><br/><br/><em>- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers</em></p> <p align="center"><em>- Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma</em></p> <p>CHICAGO and FORT WORTH, Texas, June 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics%E2%80%99+Elraglusib+Selected+for+Evaluation+in+BEACON2+Trial+for+High-Risk+Pediatric+Neuroblastoma/26620358.html Tue, 09 Jun 2026 07:45:00 -0400 A.14055798 A.23386119 ACTU O.00573638 O.00847036 O.46993908 http://www.streetinsider.com/Corporate+News/Actuate+presents+ASCO+data+showing+survival+gains+for+pancreatic+cancer+drug/26578951.html <p>Actuate Therapeutics Inc. (NASDAQ: ACTU) presented clinical data at the American Society of Clinical Oncology Annual Meeting showing survival improvements for patients with metastatic pancreatic cancer treated with its drug elraglusib combined with standard chemotherapy regimens.</p><p>The company reported results from two studies examining elraglusib in previously untreated metastatic pancreatic ductal adenocarcinoma patients. In a randomized Phase 2 study, patients with KRAS wild-type tumors who received elraglusib plus gemcitabine/nab-paclitaxel achieved median overall survival of 16.9 months compared to 10.1 months for those receiving chemotherapy alone.</p><p>Patients with P53 wild-type genomics receiving elraglusib combination therapy showed median overall survival of 13.4 months versus http://www.streetinsider.com/Corporate+News/Actuate+presents+ASCO+data+showing+survival+gains+for+pancreatic+cancer+drug/26578951.html Mon, 01 Jun 2026 07:01:44 -0400 ACTU http://www.streetinsider.com/FDA/Actuate+presents+ASCO+data+showing+survival+gains+for+pancreatic+cancer+drug/26578951.html <p>Actuate Therapeutics Inc. (NASDAQ: ACTU) presented clinical data at the American Society of Clinical Oncology Annual Meeting showing survival improvements for patients with metastatic pancreatic cancer treated with its drug elraglusib combined with standard chemotherapy regimens.</p><p>The company reported results from two studies examining elraglusib in previously untreated metastatic pancreatic ductal adenocarcinoma patients. In a randomized Phase 2 study, patients with KRAS wild-type tumors who received elraglusib plus gemcitabine/nab-paclitaxel achieved median overall survival of 16.9 months compared to 10.1 months for those receiving chemotherapy alone.</p><p>Patients with P53 wild-type genomics receiving elraglusib combination therapy showed median overall survival of 13.4 months versus http://www.streetinsider.com/FDA/Actuate+presents+ASCO+data+showing+survival+gains+for+pancreatic+cancer+drug/26578951.html Mon, 01 Jun 2026 07:01:44 -0400 ACTU http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html <p align="center"><em>- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone</em></p> <p align="center"><em>- Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone</em></p> <p align="center"><em>- Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses and increased mOS versus FOLFIRINOX alone or in combination with losartan</em></p> <p align="center"><em>- Elraglusib treatment was well tolerated when used in combination with either GnP or FOLFIRINOX</em></p> <p align="justify">CHICAGO and FORT WORTH, Texas, June 01, 2026 http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html Mon, 01 Jun 2026 07:00:00 -0400 A.50209015 A.50216726 ACTU O.00225875 O.21612337 O.46993908 http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html <p align="center"><em>- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone</em></p> <p align="center"><em>- Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone</em></p> <p align="center"><em>- Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses and increased mOS versus FOLFIRINOX alone or in combination with losartan</em></p> <p align="center"><em>- Elraglusib treatment was well tolerated when used in combination with either GnP or FOLFIRINOX</em></p> <p align="justify">CHICAGO and FORT WORTH, Texas, June 01, 2026 http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html Mon, 01 Jun 2026 07:00:00 -0400 A.50209015 A.50216726 ACTU O.00225875 O.21612337 O.46993908 http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html <p align="center"><em>- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone</em></p> <p align="center"><em>- Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone</em></p> <p align="center"><em>- Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses and increased mOS versus FOLFIRINOX alone or in combination with losartan</em></p> <p align="center"><em>- Elraglusib treatment was well tolerated when used in combination with either GnP or FOLFIRINOX</em></p> <p align="justify">CHICAGO and FORT WORTH, Texas, June 01, 2026 http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html Mon, 01 Jun 2026 07:00:00 -0400 A.50209015 A.50216726 ACTU O.00225875 O.21612337 O.46993908 http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html <p align="center"><em>- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone</em></p> <p align="center"><em>- Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone</em></p> <p align="center"><em>- Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses and increased mOS versus FOLFIRINOX alone or in combination with losartan</em></p> <p align="center"><em>- Elraglusib treatment was well tolerated when used in combination with either GnP or FOLFIRINOX</em></p> <p align="justify">CHICAGO and FORT WORTH, Texas, June 01, 2026 http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html Mon, 01 Jun 2026 07:00:00 -0400 A.50209015 A.50216726 ACTU O.00225875 O.21612337 O.46993908 http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html <p align="center"><em>- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone</em></p> <p align="center"><em>- Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone</em></p> <p align="center"><em>- Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses and increased mOS versus FOLFIRINOX alone or in combination with losartan</em></p> <p align="center"><em>- Elraglusib treatment was well tolerated when used in combination with either GnP or FOLFIRINOX</em></p> <p align="justify">CHICAGO and FORT WORTH, Texas, June 01, 2026 http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html Mon, 01 Jun 2026 07:00:00 -0400 A.50209015 A.50216726 ACTU O.00225875 O.21612337 O.46993908 http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html <p align="center"><em>- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone</em></p> <p align="center"><em>- Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone</em></p> <p align="center"><em>- Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses and increased mOS versus FOLFIRINOX alone or in combination with losartan</em></p> <p align="center"><em>- Elraglusib treatment was well tolerated when used in combination with either GnP or FOLFIRINOX</em></p> <p align="justify">CHICAGO and FORT WORTH, Texas, June 01, 2026 http://www.streetinsider.com/Press+Releases/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html Mon, 01 Jun 2026 07:00:00 -0400 A.50209015 A.50216726 ACTU O.00225875 O.21612337 O.46993908 http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html <p align="center"><em>- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone</em></p> <p align="center"><em>- Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone</em></p> <p align="center"><em>- Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses and increased mOS versus FOLFIRINOX alone or in combination with losartan</em></p> <p align="center"><em>- Elraglusib treatment was well tolerated when used in combination with either GnP or FOLFIRINOX</em></p> <p align="justify">CHICAGO and FORT WORTH, Texas, June 01, 2026 http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html Mon, 01 Jun 2026 07:00:00 -0400 A.50209015 A.50216726 ACTU O.00225875 O.21612337 O.46993908 http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html <p align="center"><em>- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone</em></p> <p align="center"><em>- Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone</em></p> <p align="center"><em>- Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses and increased mOS versus FOLFIRINOX alone or in combination with losartan</em></p> <p align="center"><em>- Elraglusib treatment was well tolerated when used in combination with either GnP or FOLFIRINOX</em></p> <p align="justify">CHICAGO and FORT WORTH, Texas, June 01, 2026 http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html Mon, 01 Jun 2026 07:00:00 -0400 A.50209015 A.50216726 ACTU O.00225875 O.21612337 O.46993908 http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html <p align="center"><em>- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone</em></p> <p align="center"><em>- Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone</em></p> <p align="center"><em>- Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses and increased mOS versus FOLFIRINOX alone or in combination with losartan</em></p> <p align="center"><em>- Elraglusib treatment was well tolerated when used in combination with either GnP or FOLFIRINOX</em></p> <p align="justify">CHICAGO and FORT WORTH, Texas, June 01, 2026 http://www.streetinsider.com/Globe+Newswire/Actuate+Therapeutics+Announces+ASCO+Poster+Presentations+Demonstrating+Compelling+Clinical+and+Biomarker+Data+for+Elraglusib+in+First-Line+Metastatic+Pancreatic+Cancer/26578922.html Mon, 01 Jun 2026 07:00:00 -0400 A.50209015 A.50216726 ACTU O.00225875 O.21612337 O.46993908